Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates

17 Pág.

Detalhes bibliográficos
Autores: Pérez Ramírez, Patricia, Albericio, Guillermo, Astorgano, David, Flores, Sara, Sánchez-Corzo, Cristina, Sánchez-Cordón, Pedro J., Luczkowiak, Joanna, Delgado, Rafael, Casasnovas, José María, Esteban, Mariano, García-Arriaza, Juan
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/349371
Acesso em linha:http://hdl.handle.net/10261/349371
https://api.elsevier.com/content/abstract/scopus_id/85180695762
Access Level:acceso abierto
Palavra-chave:COVID-19
MVA-based vaccine
S protein
SARS-CoV-2
Efficacy
Immunogenicity
Mice
Variants of concern
id ES_72911e5649969ffa007e5da32afa3fe2
oai_identifier_str oai:digital.csic.es:10261/349371
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
title Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
spellingShingle Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
Pérez Ramírez, Patricia
COVID-19
MVA-based vaccine
S protein
SARS-CoV-2
Efficacy
Immunogenicity
Mice
Variants of concern
title_short Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
title_full Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
title_fullStr Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
title_full_unstemmed Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
title_sort Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates
dc.creator.none.fl_str_mv Pérez Ramírez, Patricia
Albericio, Guillermo
Astorgano, David
Flores, Sara
Sánchez-Corzo, Cristina
Sánchez-Cordón, Pedro J.
Luczkowiak, Joanna
Delgado, Rafael
Casasnovas, José María
Esteban, Mariano
García-Arriaza, Juan
author Pérez Ramírez, Patricia
author_facet Pérez Ramírez, Patricia
Albericio, Guillermo
Astorgano, David
Flores, Sara
Sánchez-Corzo, Cristina
Sánchez-Cordón, Pedro J.
Luczkowiak, Joanna
Delgado, Rafael
Casasnovas, José María
Esteban, Mariano
García-Arriaza, Juan
author_role author
author2 Albericio, Guillermo
Astorgano, David
Flores, Sara
Sánchez-Corzo, Cristina
Sánchez-Cordón, Pedro J.
Luczkowiak, Joanna
Delgado, Rafael
Casasnovas, José María
Esteban, Mariano
García-Arriaza, Juan
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Sanidad (España)
Instituto de Salud Carlos III
Conferencia de Rectores de las Universidades Españolas
Consejo Superior de Investigaciones Científicas (España)
Fundación la Caixa
Ministerio de Ciencia e Innovación (España)
Agencia Estatal de Investigación (España)
European Commission
Albericio, Guillermo [0000-0003-0190-4848]
Astorgano, David [0000-0002-2969-1840]
Sánchez-Cordón, P. J. [0000-0002-7202-6475]
Luczkowiak, Joanna [0000-0001-6950-9372]
Delgado, Rafael [0000-0002-6912-4736]
Esteban, Mariano [0000-0003-0846-2827]
García-Arriaza, Juan [0000-0002-5167-5724]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv COVID-19
MVA-based vaccine
S protein
SARS-CoV-2
Efficacy
Immunogenicity
Mice
Variants of concern
topic COVID-19
MVA-based vaccine
S protein
SARS-CoV-2
Efficacy
Immunogenicity
Mice
Variants of concern
description 17 Pág.
publishDate 2023
dc.date.none.fl_str_mv 2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/349371
https://api.elsevier.com/content/abstract/scopus_id/85180695762
url http://hdl.handle.net/10261/349371
https://api.elsevier.com/content/abstract/scopus_id/85180695762
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-114481RB-I00
info:eu-repo/grantAgreement/EC/H2020/731868
Frontiers in immunology
https://doi.org/10.3389/fimmu.2023.1264323
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410745204080640
spelling Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidatesPérez Ramírez, PatriciaAlbericio, GuillermoAstorgano, DavidFlores, SaraSánchez-Corzo, CristinaSánchez-Cordón, Pedro J.Luczkowiak, JoannaDelgado, RafaelCasasnovas, José MaríaEsteban, MarianoGarcía-Arriaza, JuanCOVID-19MVA-based vaccineS proteinSARS-CoV-2EfficacyImmunogenicityMiceVariants of concern17 Pág.The constant appearance of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs) has jeopardized the protective capacity of approved vaccines against coronavirus disease-19 (COVID-19). For this reason, the generation of new vaccine candidates adapted to the emerging VoCs is of special importance. Here, we developed an optimized COVID-19 vaccine candidate using the modified vaccinia virus Ankara (MVA) vector to express a full-length prefusion-stabilized SARS-CoV-2 spike (S) protein, containing 3 proline (3P) substitutions in the S protein derived from the beta (B.1.351) variant, termed MVA-S(3Pbeta). Preclinical evaluation of MVA-S(3Pbeta) in head-to-head comparison to the previously generated MVA-S(3P) vaccine candidate, expressing a full-length prefusion-stabilized Wuhan S protein (with also 3P substitutions), demonstrated that two intramuscular doses of both vaccine candidates fully protected transgenic K18-hACE2 mice from a lethal challenge with SARS-CoV-2 beta variant, reducing mRNA and infectious viral loads in the lungs and in bronchoalveolar lavages, decreasing lung histopathological lesions and levels of proinflammatory cytokines in the lungs. Vaccination also elicited high titers of anti-S Th1-biased IgGs and neutralizing antibodies against ancestral SARS-CoV-2 Wuhan strain and VoCs alpha, beta, gamma, delta, and omicron. In addition, similar systemic and local SARS-CoV-2 S-specific CD4+ and CD8+ T-cell immune responses were elicited by both vaccine candidates after a single intranasal immunization in C57BL/6 mice. These preclinical data support clinical evaluation of MVA-S(3Pbeta) and MVA-S(3P), to explore whether they can diversify and potentially increase recognition and protection of SARS-CoV-2 VoCs.The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by Fondo COVID-19 grant COV20/00151 (Spanish Health Ministry, Instituto de Salud Carlos III (ISCIII)), Fondo Supera COVID-19 grant (Crue Universidades-Banco Santander), and Spanish Research Council (CSIC) grant 202120E079 (to JG-A); CSIC grant 2020E84, la Caixa Banking Foundation grant CF01-00008, Ferrovial, and MAPFRE donations (to ME); and Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RB-I00; to JG-A and ME). This research work was also funded by the European Commission-Next Generation EU, through CSIC’s Global Health Platform (PTI Salud Global) (to JG-A and ME). JG-A and ME acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). JC acknowledges MCIN and CSIC support (project number 202020E079). RD received grants from ISCIII (FIS PI2100989), the European Commission Horizon 2020 Framework Programme (Project VIRUSCAN FETPROACT-2016: 731868 and Project EPIC-CROWN-2: 101046084), and Fundacioín Caixa-Health Research HR18-00469 (Project StopEbola).Peer reviewedFrontiers MediaMinisterio de Sanidad (España)Instituto de Salud Carlos IIIConferencia de Rectores de las Universidades EspañolasConsejo Superior de Investigaciones Científicas (España)Fundación la CaixaMinisterio de Ciencia e Innovación (España)Agencia Estatal de Investigación (España)European CommissionAlbericio, Guillermo [0000-0003-0190-4848]Astorgano, David [0000-0002-2969-1840]Sánchez-Cordón, P. J. [0000-0002-7202-6475]Luczkowiak, Joanna [0000-0001-6950-9372]Delgado, Rafael [0000-0002-6912-4736]Esteban, Mariano [0000-0003-0846-2827]García-Arriaza, Juan [0000-0002-5167-5724]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202420242023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/349371https://api.elsevier.com/content/abstract/scopus_id/85180695762reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-114481RB-I00info:eu-repo/grantAgreement/EC/H2020/731868Frontiers in immunologyhttps://doi.org/10.3389/fimmu.2023.1264323Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3493712026-05-22T06:33:51Z
score 15.812429

Registos relacionados